About Us | Contact

Yehudith Assouline-Dayan Investigator

Holy Family Hospital NPI1093141228
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$14,819.40
from 33 payments in the last 6 years

Total Cash or Cash Equivalent

$2,978.16
from 10 payments in the last 6 years

Total In-kind Items & Services

$11,841.24
from 23 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
09/29/2021 General (Non-Research) In-kind items and services Food and Beverage $18.91 Details
Payment from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payment Record ID 850241951
07/22/2021 General (Non-Research) In-kind items and services Food and Beverage $26.91 Details
Payment from Takeda Pharmaceuticals U.S.A., Inc.
Payment Record ID 819854625
01/11/2020 General (Non-Research) In-kind items and services Travel and Lodging $772.82 Details
Payment from Adare Pharmaceuticals, Inc.
Payment Record ID 750444579
01/11/2020 General (Non-Research) In-kind items and services Food and Beverage $170.49 Details
Payment from Adare Pharmaceuticals, Inc.
Payment Record ID 750444289
01/09/2020 General (Non-Research) In-kind items and services Food and Beverage $152.02 Details
Payment from Adare Pharmaceuticals, Inc.
Payment Record ID 750444287
01/11/2020 General (Non-Research) In-kind items and services Travel and Lodging $219.52 Details
Payment from Adare Pharmaceuticals, Inc.
Payment Record ID 750444285
03/31/2020 Research In-kind items and services Biological $33.90 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF DUPILUMAB IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
Clinical Trials Gov ID NCT02379052
Payment Record ID 724430481
12/06/2019 Research In-kind items and services Biological $162.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF DUPILUMAB IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
Clinical Trials Gov ID NCT02379052
Payment Record ID 639752157
11/19/2019 Research In-kind items and services Biological $1875.50 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF DUPILUMAB IN ADULT PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
Clinical Trials Gov ID NCT02379052
Payment Record ID 639752155
06/04/2019 Research In-kind items and services Biological $63.32 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE
Clinical Trials Gov ID NCT03633617
Payment Record ID 639752153
06/04/2019 Research In-kind items and services Biological $24.47 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE
Clinical Trials Gov ID NCT03633617
Payment Record ID 639752151
05/04/2019 Research In-kind items and services Biological $875.30 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE
Clinical Trials Gov ID NCT03633617
Payment Record ID 639752149
05/04/2019 Research In-kind items and services Biological $130.00 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE
Clinical Trials Gov ID NCT03633617
Payment Record ID 639752147
05/03/2019 Research In-kind items and services Biological $103.75 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE
Clinical Trials Gov ID NCT03633617
Payment Record ID 639752145
04/05/2018 Research In-kind items and services Drug $3205.00 Details
Payment from Celgene Corporation
Paymment Research Study RPC02-201
Payment Record ID 595027259
09/30/2018 Research Cash or cash equivalent Biological $165.23 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Clinical Trials Gov ID NCT02379052
Payment Record ID 577362845
09/30/2018 Research Cash or cash equivalent Biological $131.82 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Clinical Trials Gov ID NCT02379052
Payment Record ID 577362837
07/04/2018 Research Cash or cash equivalent Biological $501.33 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study DUPIXENT CLINICAL DEVELOPMENT PROGRAM
Payment Record ID 577362833
07/04/2018 Research Cash or cash equivalent Biological $530.82 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study DUPIXENT CLINICAL DEVELOPMENT PROGRAM
Payment Record ID 577362829
06/19/2018 Research Cash or cash equivalent Biological $247.83 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study DUPIXENT CLINICAL DEVELOPMENT PROGRAM
Payment Record ID 577362825
02/20/2018 Research Cash or cash equivalent Biological $130.67 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Clinical Trials Gov ID NCT02379052
Payment Record ID 577362819
02/13/2018 Research Cash or cash equivalent Biological $179.37 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Clinical Trials Gov ID NCT02379052
Payment Record ID 577362817
02/13/2018 Research Cash or cash equivalent Biological $189.92 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Clinical Trials Gov ID NCT02379052
Payment Record ID 577362811
01/18/2018 Research In-kind items and services $111.38 Details
Payment from Allergan Inc.
Paymment Research Study 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS
Payment Record ID 576656709
01/18/2018 Research In-kind items and services $10.21 Details
Payment from Allergan Inc.
Paymment Research Study 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS
Payment Record ID 576656707
01/18/2018 Research In-kind items and services $6.37 Details
Payment from Allergan Inc.
Paymment Research Study 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS
Payment Record ID 576656705
01/18/2018 Research In-kind items and services $9.64 Details
Payment from Allergan Inc.
Paymment Research Study 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS
Payment Record ID 576656703
01/18/2018 Research In-kind items and services $454.84 Details
Payment from Allergan Inc.
Paymment Research Study 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS
Payment Record ID 576656701
07/28/2018 General (Non-Research) In-kind items and services Food and Beverage $47.89 Details
Payment from Shire North American Group Inc
Payment Record ID 565823440
12/01/2017 Research In-kind items and services Drug $417.00 Details
Payment from Celgene Corporation
Paymment Research Study RPC02-201 HEREOS study
Payment Record ID 493258035
12/04/2017 Research In-kind items and services Drug $2950.00 Details
Payment from Celgene Corporation
Paymment Research Study RPC02-201
Payment Record ID 493258031
10/26/2017 Research Cash or cash equivalent Biological $721.80 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Clinical Trials Gov ID NCT02379052
Payment Record ID 485423699
10/16/2017 Research Cash or cash equivalent Biological $179.37 Details
Payment from Regeneron Pharmaceuticals, Inc.
Paymment Research Study A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Clinical Trials Gov ID NCT02379052
Payment Record ID 485423697
;